Hematocrit Test Devices Market Size, Share and Global Trend By Product Type (Blood Analysers, Hematocrit Meters, Others), By Application (Lymphoma, Leukemia, Anemia, Congenital Heart Diseases, Others), By End User (Hospitals, Diagnostic Centres, Specialty Clinics, Ambulatory Surgery Centres, Home Healthcare, Others) and Regional Forecast, 2024-2032

A blood test can detect many disease conditions from fever to cancer. Hematocrit is a type of blood test performed to measure the proportion of a person's total blood volume that is composed of red blood cells (RBCs). The hematocrit is defined as the ratio of the volume of red blood cells to the volume of blood. The hematocrit test is used to screen or diagnose various conditions and diseases that can affect the portion of blood made up of red blood cells (RBCs).

The hematocrit test is usually performed for the diagnosis of conditions such as anemia, leukemia, enlarged spleen, pulmonary diseases, and others. In addition, hematocrit test devices are also available which gives the results at a short span of time.

The launch of new technically advanced products is favoring the expansion of global hematocrit test devices market. For example, in December 2018, Sysmex Corporation, one of the manufacturers of diagnostic instruments launched CN-6000 and CN-3000, a next-generation automated blood analyzer. In 2016, researchers developed thermometer-like strip-based microfluidic devices for measuring the hematocrit. The paper-based microfluidic devices has emerged as a platform to develop diagnostic assays specifically for use at the point-of-care. The technological advancements in the haematocrit tests is one of the major factor driving the growth of the global hemotocrit test devices market. 

However, high expenditure in research and development of the new products, and lack of awareness about importance of hematocrit tests in the diagnosis of diseases are the major factors that hinder the growth of the global hematocrit test devices market.

Key Players Covered

Some of the major companies that are present in the global Hematocrit test devices market are Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, EKF Diagnostics – Stanbio, Nova Biomedical, NIHON KOHDEN CORPORATION, Sysmex Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., HORIBA, Ltd., Boule Diagnostics AB and other players.

SEGMENTATION

In 2018, among application, anemia dominated the global hematocrit test devices market, owing to the increased prevalence of anemia especially among women and improved health reforms to tackle anemia.

Key Insights

• Epidemiology of blood diseases by key countries


• New Product Launches, by Key Market Players


• Pricing Analysis, by Key Regions/ Key Countries


• Technological advancements in hematocrit test devices


• Key Mergers & Acquisitions

Regional Analysis

The global hematocrit test devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In North America, the hematocrit test devices market is expected to have significant growth during the forecast period owing to the increasing adoption of point of care hematocrit devices due to its ability to give quick results. According to The Leukaemia & Lymphoma Society, over 174,250 people in the U.S are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018, subsequently increasing the demand for blood tests, which will further boost the hematocrit test devices market in North America. The hematocrit test devices market in Europe and the Asia Pacific is projected to expand in the forecast period due to the high prevalence of anemia in women and incaresed awareness of blood testing.

Key Industry Developments

• In December 2018, Sysmex Corporation, one of the manufacturers of diagnostic instruments launched CN-6000 and CN-3000, a next-generation automated blood analysers.
• In May 2018, Nova Biomedical announced the launch of StatStrip Hemoglobin and Hematocrit Meter System, which is now available in all countries accepting CE mark. 
• In November 2017, Sysmex Corporation received CLIA-waiver certification from the U.S. approval authorities for their automatic haematology analysing product XW-100, resulting its expansion in the U.S market.
• In January 2017, F. Hoffmann-La Roche Ltd., announced the launch of Cobas m 511, an integrated haematology analyser in countries accepting CE mark. The launch is considered as a remarkable entry of Roche Diagnostics in the haematocrit market.